1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: other
Guangdong Jiaying Pharmaceutical Co., Ltd. Class A

Guangdong Jiaying Pharmaceutical Co., Ltd. Class A

SSZSE:002198
3.23
CNY
+0.02
(+0.62%)
1.54BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.53
1.11
0.94
0.89
0.92
1.06
0.99
1.07
1.13
1.3
1.05
0.74
0.76
- -
Basic EPS, GAAP
0.33
0.15
0.13
0.11
-0.42
0.07
-0.24
0.04
- -
0.09
0.07
0.04
0.06
- -
Free Cash Flow per Basic Share
0.03
0.01
0.02
0.08
0.02
0.1
-0.01
0.17
0.1
0.05
0.18
0.04
-0.2
- -
Dividend per Share
0.02
0.04
- -
- -
0.04
- -
0.01
0.01
- -
- -
- -
0.05
- -
- -
Book Value per Share
1.6
1.7
1.83
1.94
1.48
1.55
1.31
1.35
1.35
1.44
1.5
1.49
1.41
1.39
Tangible Book Value per Share
0.74
0.8
0.94
1.06
1.08
1.16
1.17
1.22
1.23
1.33
1.41
1.4
1.26
1.23
Basic Weighted Avg Shares
426
508
508
508
507
508
507
507
509
507
508
508
507
531
Sales/Revenue/Turnover
227
566
476
450
468
537
501
545
575
659
533
376
384
- -
Operating Margin (%)
12.7
14.4
15.74
15.72
8.22
8.73
1.89
6.06
5.15
8.3
7
7.13
11.64
- -
Depreciation Expense
15
23
21
26
27
27
27
28
28
26
24
20
21
- -
Net Income, GAAP
139
74
66
55
-215
36
-122
20
1
44
34
21
30
- -
Effective Tax Rate (%)
22.21
15.64
15.18
17.19
- -
15.24
- -
13.83
74.63
14.02
12.83
17.87
19.69
- -
Profit Margin (%)
61.52
13.02
13.95
12.26
-45.88
6.68
-24.41
3.64
0.26
6.66
6.44
5.48
7.94
- -
Working Capital
197
167
210
271
281
335
252
344
402
474
531
508
406
385
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
810
863
930
985
750
785
663
683
684
728
763
758
718
705
Return on Invested Capital (%)
24.33
7.41
6.76
5.58
- -
4.47
- -
2.88
0.19
6.4
4.71
2.73
4.35
- -
Return on Capital (%)
25.08
8.77
7.37
5.74
- -
4.69
- -
3.18
0.24
6.14
4.6
2.71
4.15
- -
Return on Common Equity (%)
25.65
8.81
7.4
5.76
-24.76
4.67
-16.87
2.95
0.22
6.22
4.6
2.71
4.13
- -

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
- -
20
20
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
508
508
508
Market Capitalization
3,568
3,898
1,538

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
503
542
493
Cash, Cash Equivalents & STI
177
152
128
Accounts Receivable, Net
137
199
166
Inventories
74
57
107
Total Current Liabilities
96
127
107
Payables & Accruals
- -
- -
- -
ST Debt
- -
20
20
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-2.03%
1.09%
-5.31%
Free Cash Flow
-148.01%
-88.42%
-555.75%
Net Income, GAAP
158.79%
553.51%
47.87%
Sales/Revenue/Turnover
-1.1%
-5.27%
2.02%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
94
86
79
117
376
2025
122
77
- -
90
384
2026
123
43
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
- -
-0.01
0.03
0.04
2025
0.03
0.01
- -
0.02
0.06
2026
0.02
-0.05
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.05
- -
- -
0.05
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Yong Ping You
Full Time Employees
594
Sector
Health technology
Industry
Pharmaceuticals: other
Address
Dongsheng Industrial Park Meizhou GD China 514071
IPO Date
Dec 18, 2007
Website
gdjyzy.com.cn
Similar Companies
Cipla Ltd (NSE:CIPLA)
Aurobindo Pharma Ltd (NSE:AUROPHARMA)
Lupin Limited (NSE:LUPIN)
Granules India Limited (NSE:GRANULES)
Revolution Medicines, Inc. (NASDAQ:RVMD)
Egyptian International Pharmaceutical Industries Co. (EGX:PHAR)
Business
Guangdong Jiaying Pharmaceutical Co., Ltd. engages in the research, development, production and sales of Chinese patent medicines primarily in mainland China. The company offers a range of products targeting throat ailments, colds, orthopedics, rheumatism, gynecology, heat-clearing, tonics and gastrointestinal diseases, including Shuangliao Houfeng Powder and Lozenges, Chongganling Tablets, Yinqiao Jiedu Granules, Juhong Tanke Granules, Jieguqili Tablets and Capsules, Xiaoyan Lidan Tablets, Jinju Wuhua Tea Granules, Zhuangyao Jianshen Pills, Guifu Lizhong Pills, Shuangliang Throat Fung, Zongying Tablets, Orange Red Phlegm Cough Tablets, Seven Centigrade Bone Capsules, Anti-inflammatory Biliary Tablets, Waist Strengthening and Kidney Pills, Guizheng Ginseng Pills, Guzhouli Medium Pills, Stomach Pain Tablets and Diarrhoea and Stomach Pain Capsules. Founded in 2003 through the restructuring of Meizhou Pharmaceutical Factory and headquartered in Area B, Dongsheng Industrial Park, Meizhou City, Guangdong Province, the company listed on the Shenzhen Stock Exchange in December 2007 and distributes its products mainly within the domestic market with some exports to Taiwan, Hong Kong, Macau, Southeast Asia, Europe and America. In recent developments, senior executives faced fines from the Guangdong Securities Regulatory Bureau for information disclosure violations as part of an investigation initiated in May 2025 by the China Securities Regulatory Commission; additionally, Guangdong New South Investment Co., Ltd. entered into a share transfer agreement to acquire a 12.21% stake in the company. From September to December 2024, the company launched a proprietary Chinese medicine transaction with Kyoho Pharmaceutical. The company employs approximately 594 people and holds designations as a high-tech enterprise and key protection entity for its protected traditional Chinese medicine varieties.